DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
OTHER
Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
BREAST
(Journal) Therapeutic Advances in Medical Oncology
2021
KELLY
Pembrolizumab plus eribulin in hormone-receptore positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label,multicentre, single-arm, phase II trial
BREAST
(Journal) European Journal of Cancer
2021
DEBBRAH
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study
BREAST
SABCS
2021
PARSIFAL
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive,ERBB2-Negative Advanced Breast Cancer A Randomized Clinical Trial
BREAST
(Journal) JAMA Oncology
2021
AZENT
First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met
LUNG
(Journal) European Journal of Cancer
2021
PECATI
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients
THYMIC
(Journal) Clinical Lung Cancer
2021
PHERGAIN
SUBSTUDY - LINGAIN: Analysis of αβ and γδ circulating T cells in the PHERGain randomized phase 2 trial for patients with HER2-positive early breast cancer receiving neoadjuvant trastuzumab and pertuzumab without chemotherapy: LINGain
BREAST
SABCS
2021
METALLICA
Metaformin in the prevention of hyperglycemia in patients with PIK#CA-mutated, hormone receptor (HR)[+]/HER2[-] advanced breast cancer treated with alpelisib plus fulvestrant: METALLICA study
BREAST
ESMO Breast
2021
OTHER
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
BREAST
(Journal) npj Breast Cancer
2021
OTHER
Nobody dares stopping clinical research, not even COVID-19
COVID-19
(Journal) npj Breast Cancer
2021
SLLIP
Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testingin advanced non-small cell lung cancer
LUNG
(Journal) JCO Precision Oncology
2021
OTHER
CDK4/6 inhibitors in breast cancer: spotting the difference
BREAST
(Journal) Cancer Therapy
2021
Other MEDSIR related articles
"